Claudia Wellbrock
  • Manchester Cancer Research Centre, Wellcome Trust Centre for Cell Matrix Research, Faculty of Life Sciences, The University of Manchester, UK
  • Cancer Biology
Personal information


Ph.D. in Biochemistry, Department of Physiological Chemistry, University of Würzburg, Germany

Current position

Professor of Cancer Biology, University of Manchester, UK

Publications (since 2005)

  1. Wellbrock, C. (2015). Spatial intra-tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co-clinical cancer studies. EMBO Mol Med 7(9): 1087-1089.
  2. Wellbrock, C. and Arozarena, I. (2015). Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. Pigment Cell Melanoma Res 28(4): 390-406.
  3. Erice, O., Smith, M. P., White, R., Goicoechea, I., Barriuso, J., Jones, C., Margison, G. P., Acosta, J. C., Wellbrock, C.* and Arozarena, I.* (2015). MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide. Mol Cancer Ther 14(5): 1236-1246. (*Corresponding authors)
  4. Smith, M. P., Sanchez-Laorden, B., O'Brien, K., Brunton, H., Ferguson, J., Young, H., Dhomen, N., Flaherty, K. T., Frederick, D. T., Cooper, Z. A., Wargo, J. A., Marais, R. and Wellbrock, C. (2014). The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha. Cancer Discov 4(10): 1214-1229.
  5. Chapman, A., Fernandez del Ama, L., Ferguson, J., Kamarashev, J., Wellbrock, C.* and Hurlstone, A.* (2014). Heterogeneous tumor subpopulations cooperate to drive invasion. Cell Rep 8(3): 688-695.
  6. Wellbrock, C. (2014). MAPK pathway inhibition in melanoma: resistance three ways. Biochem Soc Trans 42(4): 727-732.
  7. Hurlstone, A. and Wellbrock, C. (2014). TP53 in the UV spotlight: a bona fide driver of melanoma. Pigment Cell Melanoma Res 27(6): 1010-1011.
  8. Arozarena, I., Goicoechea, I., Erice, O., Ferguson, J., Margison, G. P. and Wellbrock, C. (2014). Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. Mol Cancer 13: 154.
  9. Atkin, J., Halova, L., Ferguson, J., Hitchin, J. R., Lichawska-Cieslar, A., Jordan, A. M., Pines, J., Wellbrock, C. and Petersen, J. (2014). Torin1-mediated TOR kinase inhibition reduces Wee1 levels and advances mitotic commitment in fission yeast and HeLa cells. J Cell Sci 127(Pt 6): 1346-1356.
  10. Smith, M. P., Ferguson, J., Arozarena, I., Hayward, R., Marais, R., Chapman, A., Hurlstone, A. and Wellbrock, C. (2013). Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J Natl Cancer Inst 105(1): 33-46.
  11. Ferguson, J., Arozarena, I., Ehrhardt, M. and Wellbrock, C. (2013). Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. Oncogene 32(1): 86-96.
  12. Arozarena, I., Bischof, H., Gilby, D., Belloni, B., Dummer, R. and Wellbrock, C. (2011). In melanoma, beta-catenin is a suppressor of invasion. Oncogene 30(45): 4531-4543.
  13. Wellbrock, C. and Hurlstone, A. (2010). BRAF as therapeutic target in melanoma. Biochem Pharmacol 80(5): 561-567.
  14. Rennalls, L. P., Seidl, T., Larkin, J. M., Wellbrock, C., Gore, M. E., Eisen, T. and Bruno, L. (2010). The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells. Immunology 129(4): 610-619.
  15. Wellbrock, C., Rana, S., Paterson, H., Pickersgill, H., Brummelkamp, T. and Marais, R. (2008). Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One 3(7): e2734.
  16. Hassel, J. C., Winnemoller, D., Schartl, M. and Wellbrock, C. (2008). STAT5 contributes to antiapoptosis in melanoma. Melanoma Res 18(6): 378-385.
  17. Gray-Schopfer, V., Wellbrock, C. and Marais, R. (2007). Melanoma biology and new targeted therapy. Nature 445(7130): 851-857.
  18. Pardo, O. E., Wellbrock, C., Khanzada, U. K., Aubert, M., Arozarena, I., Davidson, S., Bowen, F., Parker, P. J., Filonenko, V. V., Gout, I. T., Sebire, N., Marais, R., Downward, J. and Seckl, M. J. (2006). FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J 25(13): 3078-3088.
  19. Meierjohann, S., Wende, E., Kraiss, A., Wellbrock, C. and Schartl, M. (2006). The oncogenic epidermal growth factor receptor variant Xiphophorus melanoma receptor kinase induces motility in melanocytes by modulation of focal adhesions. Cancer Res 66(6): 3145-3152.
  20. Winnemoeller, D., Wellbrock, C. and Schartl, M. (2005). Activating mutations in the extracellular domain of the melanoma inducing receptor Xmrk are tumorigenic in vivo. Int J Cancer 117(5): 723-729.
  21. Wellbrock, C., Weisser, C., Hassel, J. C., Fischer, P., Becker, J., Vetter, C. S., Behrmann, I., Kortylewski, M., Heinrich, P. C. and Schartl, M. (2005). STAT5 contributes to interferon resistance of melanoma cells. Curr Biol 15(18): 1629-1639.
  22. Wellbrock, C. and Marais, R. (2005). Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol 170(5): 703-708.